5-Star Stocks Poised to Pop: Medtronic
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device giant Medtronic (NYS: MDT) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Medtronic's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Minneapolis (1949)|
|Market Cap||$40.6 billion|
|Trailing-12-Month Revenue||$16.4 billion|
|Management||Chairman/CEO Omar Ishrak|
CFO Gary Ellis
|Return on Equity (Average, Past 3 Years)||20%|
|Cash/Debt||$2.17 billion / $10.3 billion|
Johnson & Johnson
St. Jude Medical
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 95% of the 1,802 members who have rated Medtronic believe the stock will outperform the S&P 500 going forward.
Medtronic's stock has been somewhat over slashed by the market downturn this [past summer] -- I hesitate to call it a crash -- and I think the stock is headed to the mid 50s by the end of 2012. Forward earnings supports a mid 50s share price and Medtronic's dividend yield is near 2% to boot. I think this makes Medtronic an easy thumbs up since I've heard no bad news recently.
What do you think about Medtronic, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.
At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Medtronic and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.